Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Cash (2016 - 2025)

Historic Change in Cash for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $26.1 million.

  • Ultragenyx Pharmaceutical's Change in Cash rose 10789.43% to $26.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.5 million, marking a year-over-year decrease of 3323.49%. This contributed to the annual value of -$35.2 million for FY2024, which is 14308.17% down from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Change in Cash is $26.1 million, which was up 10789.43% from $49.5 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Change in Cash registered a high of $367.9 million during Q2 2024, and its lowest value of -$330.0 million during Q3 2024.
  • Its 5-year average for Change in Cash is -$26.9 million, with a median of -$29.1 million in 2023.
  • The largest annual percentage gain for Ultragenyx Pharmaceutical's Change in Cash in the last 5 years was 217923.92% (2024), contrasted with its biggest fall of 103570.76% (2024).
  • Over the past 5 years, Ultragenyx Pharmaceutical's Change in Cash (Quarter) stood at $100.0 million in 2021, then plummeted by 358.59% to -$258.7 million in 2022, then soared by 154.42% to $140.8 million in 2023, then tumbled by 82.99% to $23.9 million in 2024, then increased by 8.81% to $26.1 million in 2025.
  • Its Change in Cash was $26.1 million in Q3 2025, compared to $49.5 million in Q2 2025 and -$45.0 million in Q1 2025.